Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
- Philipp Le Coutre
- , Oliver G. Ottmann
- , Francis Giles
- , Dong Wook Kim
- , Jorge Cortes
- , Norbert Gattermann
- , Jane F. Apperley
- , Richard A. Larson
- , Elisabetta Abruzzese
- , Stephen G. O'Brien
- , Kazimierz Kuliczkowski
- , Andreas Hochhaus
- , Francois Xavier Mahon
- , Giuseppe Saglio
- , Marco Gobbi
- , Yok Lam Kwong
- , Michele Baccarani
- , Timothy Hughes
- , Giovanni Martinelli
- , Jerald P. Radich
- Charité – Universitätsmedizin Berlin
- Goethe University
- Department of Cancer Biology
- Department of Internal Medicine
- Heinrich-Heine-University
- Hammersmith Hospital
- University of Chicago
- University of Rome "Tor Vergata"
- Royal Victoria Infirmary
- Klinika Hematologii
- Heidelberg University
- Centre François Xavier Michelet
- University Hospital San Luigi Gonzaga
- IRCCS for Oncology and Neurosciences
- Queen Mary Hospital Hong Kong
- University of Bologna
- Royal Adelaide Hospital
- Fred Hutchinson Cancer Center
- Novartis Institutes for Biomedical Research
Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
279
Citations
(Scopus)